Key result
OnabotulinumtoxinA plus exercise shows no significant benefit over saline for caregiver burden or depression.
Observational (n=16)
Nonrandom sample (companion study to a pilot clinical trial)
Answers are grounded in this paper and cite their sources.
PURPOSE: To explore possible extended benefits to caregivers of stroke survivors receiving a treatment of onabotulinumtoxinA (BTX-A) or saline with a structured exercise program. DESIGN: A comparative, prospective, companion study using a nonrandom sample of 16 caregivers of stroke survivors enrolled in a pilot clinical trial comparing BTX-A or saline and exercise for upper extremity spasticity. METHODS: The caregiver measures were depressive symptoms, care demands, family conflict surrounding stroke recovery, and mental and physical health status. FINDINGS: There were no statistically significant differences between caregiver groups. Caregivers of stroke survivors who received BTX-A had a greater change in depressive symptoms that may reflect a clinically important change. Estimates of effect sizes between the groups, controlling for baseline values, indicate a trend for moderate to large effects (last evaluation) for fewer depressive symptoms (d = 0.52) and less caregiver burden (d = 0.77 time, 0.85 difficulty) for caregivers of the BTX-A group. CONCLUSIONS AND CLINICAL RELEVANCE: Receiving BTX-A did not alter caregiving demands or depressive symptoms compared to those receiving saline. Further research with larger sample sizes is needed to better understand the interdependence of stroke survivors and caregivers on the health of each.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2014) conducted an observational in Caregivers of stroke survivors with upper extremity spasticity (n=16). OnabotulinumtoxinA (BTX-A) with a structured exercise program (administered to stroke survivors) vs. Saline with a structured exercise program (administered to stroke survivors) was evaluated on Caregiver depressive symptoms, care demands, family conflict, and mental and physical health status (d = 0.52 (depressive symptoms); d = 0.77 (burden time); d = 0.85 (burden difficulty)). OnabotulinumtoxinA plus exercise for stroke survivors showed no significant differences for caregivers vs saline, with trends toward fewer depressive symptoms and less burden.
Synapse has enriched 10 related papers. Consider them for comparative context: